 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 GLOBE NEWSWIRE -- Catalyst Biosciences, Inc. NASDAQ: CBIO today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug Disease Designation ODD for its lead product candidate, subcutaneous Marzeptacog alfa activated, or MarzAA, for the treatment of Factor VII Deficiency FVIID. MarzAA was previously granted ODD and Fast Track Designation FTD for treatment of Hemophilia AB with inhibitors and FTD for the treatment of FVIID. 